



**Eosinophilic bronchiolitis: is it a new syndrome?**

Journal:	<i>European Respiratory Journal</i>
Manuscript ID:	Draft
Manuscript Type:	Editorial
Date Submitted by the Author:	n/a
Complete List of Authors:	Poletti, Venerino; Ospedale GB Morgagni, Diseases of the thorax
Key Words:	bronchiolitis, eosinophilia, asthma

1  
2  
3 Identification of new diseases or of a cluster (syndrome) of disorders with very similar pathological,  
4 radiological and clinical aspects even sharing common pathogenic steps is an important fact to build  
5 up the scientific soul of the complex and intriguing art called medicine. In literature, a new distinct  
6 syndrome, the hyperesinophilic obliterative bronchiolitis, is described by Cordier JF et al [1]. This  
7 syndrome is defined by three criteria: 1) blood eosinophil cell count > 1G/L (and/or BAL  
8 eosinophil differential cell count > 25%); 2) persistent airflow obstruction on lung function tests not  
9 modifiable after 4-6 weeks of inhaled corticosteroid therapy (2,000 micrograms/day of  
10 beclometasone or equivalent); 3) lung biopsy showing inflammatory bronchiolitis with prominent  
11 bronchiolar wall infiltration by eosinophils and/or characteristic direct HRCT features of  
12 bronchiolitis (poorly defined centrilobular nodules, branching opacities, tree in bud pattern). The  
13 first impression that a cursory Clinician and/or Pathologist has, going swiftly through this list of  
14 criteria, is that “we are dealing with a severe and persistent form of asthma”. In chronic asthma the  
15 obstructive impairment becomes fixed and not modifiable -at least easily- with steroids or  
16 bronchodilators; in chronic asthma eosinophils in lung tissue and blood may be constantly increased  
17 and HRCT shows abnormalities in between 68% and 90% of patients (bronchial wall thickening  
18 and narrowing of bronchial lumen, cylindrical bronchiectasis, thick linear opacities, areas of  
19 decreased attenuation, bronchial mucoid impaction, small centrilobular opacities, airspace  
20 consolidation, thin-walled cysts) [2]. Finally, from a pathological point of view, mucous  
21 eosinophilic plugs may fill both small bronchi and bronchioles, and marked goblet cell  
22 hyperplasia/metaplasia of bronchial/bronchiolar epithelium, thickening of the basement membrane,  
23 bronchiolar smooth muscle hypertrophy, fibrosis of the bronchiolar wall with peribronchiolar  
24 lymphoid aggregates, mixed inflammatory infiltrate with prominent eosinophils throughout airway  
25 walls are all detectable [3]. However it is clear that the concept of “severe and persistent asthma” is  
26 still poorly understood and the contribute of these Authors [1] may help to better define and  
27 appreciate the characteristics (clinical, radiographic, pathologic and biologic) of those patients that  
28 have symptoms, signs, imaging findings and even pathologic aspects as boundaries between “severe  
29 asthma” and some form of a not yet well defined bronchiolitis.

30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48 In the reported series [1] one patient had a limited form of Churg Strauss syndrome, one patient  
49 showed an aberrant population of T lymphocytes in the peripheral blood (CD3+CD4+CD7-  
50 lymphocytes) with oligoclonal T-cell receptor gamma VG9J1J2 re-arrangement suggesting a  
51 relationship with the lymphocytic variant of hypereosinophilic syndrome [4], one patient had the  
52 typical aspects of Allergic Bronchopulmonary Mycosis (as *Aspergillus* was not documented either  
53 by immunologic tests, microbiology or histology, a diagnosis of ABPA may not be sustained) [3]  
54 and, finally, in one patient -not included in the present series but part of the clinical experience of  
55  
56  
57  
58  
59  
60

1  
2  
3 the Authors- the lesion was allegedly related to minocycline use. Almost all the patients had airflow  
4 obstruction despite inhaled therapy; HRCT scan features indicated that the lesions were centered on  
5 small bronchi/bronchioles (bronchial wall thickening, “tree in bud” pattern, mucoid impaction,  
6 “finger in glove” pattern, centrilobular nodules), the burden of eosinophilic infiltrate in the airway  
7 walls was higher than expected in asthma and rather typical of cellular bronchiolitis [5]; finally in  
8 two patients bronchoscopy documented patchy tracheobronchial mucosal lesions corresponding  
9 histopathologically to ulcerated areas of necrosis and prominent eosinophilic inflammation;  
10 paranasal sinus inflammation was well documented in 4 out of 6 patients confirming that the lesions  
11 extended also to the larger respiratory airways. Improvement was observed after oral steroids or  
12 even immunosuppressor drugs use.

13  
14 The box - having as selective criteria direct CT scan findings indicating small airways disease,  
15 eosinophilic bronchiolitis and blood/BAL eosinophilia- inside which the “hypereosinophilic  
16 obliterative bronchiolitis syndrome” might be included, contains other entities or specific subset of  
17 patients.

18  
19 In Churg Strauss syndrome, it is already known that occasionally eosinophilic inflammatory lesions  
20 may primarily involve the bronchovascular bundles with minimal spread to the alveolar parenchyma  
21 [6] and bronchoscopy may detect lesions even in larger airways. Eosinophilic bronchiolitis was  
22 reported by Japanese Authors [7]: common characteristics included bronchiolitis with eosinophilic  
23 infiltration, CT scan findings similar to that observed in diffuse panbronchiolitis, ventilatory  
24 impairment, airway hyper-reactivity, and blood and BAL-fluid eosinophilia. Recently Wenzel SE et  
25 al [8] described 10 patients with clinically severe asthma with subtle CT scan lesions (only in one  
26 patient a “tree in bud pattern” was detected) and with characteristic pathologic aspects: peripheral  
27 airways showing asthmatic changes (submucosal inflammation consisting of eosinophils,  
28 neutrophils, lymphocytic transmigration, submucosal fibrosis, mucus plugging, peribronchiolar  
29 fibrosis, bronchioloectasis, muscular hypertrophy along with interstitial mononuclear pneumonia  
30 with the presence of poorly formed granulomas, lymphoid aggregates and airspace organization).  
31 The Authors [8] labeled this subset of patients as “asthmatic granulomatosis”. Interestingly, non  
32 steroidal cytotoxic drugs improved the course of the disease. The description and data collected by  
33 Cordier et al [1] add therefore some other elements of knowledge to this not yet well defined  
34 ensemble: some patients had an autoimmune disorder (Churg Strauss syndrome), an  
35 hypersensitivity behaviour (allergic bronchopulmonary mycosis), some had a dysregulation of T  
36 lymphocytes (probably including lymphocytes expressing and releasing IL-5), and some other had  
37 elements indicating a drug reaction. Therefore hypereosinophilic obliterative bronchiolitis along  
38 with other recently reported “entities” indicate that patients usually considered as affected by  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 “severe asthma” may actually have a disorder in which different biologic processes are involved but  
4 which share common elements:

- 5  
6
- 7 1. small airways are the anatomic zone more heavily involved (although the infiltrate may  
8 extend to the large airways and paranasal sinuses)
  - 9  
10 2. eosinophils are more represented cells in the morphologic lesion
  - 11  
12 3. dis-regulation of immunity (autoantibodies production, hypersensitivity, dysregulation of T  
13 cells) may have a role
  - 14  
15 4. non steroidal immunosuppressant drugs might be effective (confirming the empirical feeling  
16 of expert Clinicians).
  - 17  
18  
19  
20

21  
22 This report could open new windows drawing attention to the links between autoimmunity,  
23 hypersensitivity, T cell dysregulation, eosinophilic inflammation and bronchiolitis; it raises interest  
24 in new pathogenetic mechanisms leading to obliterative bronchiolitis, discloses links between  
25 oligoclonal T cell proliferation and bronchiolocentric eosinophilic inflammation, suggests that  
26 cytotoxic drugs or even monoclonal antibodies might have some benefit. Next step to exploit these  
27 new scenarios could be the collection of a significant number of patients with these clinical -  
28 radiological characteristics provided with pathological (and biological) data. In fact in only two  
29 patients the Authors [1] reported histopathological information. Interestingly, as the lesions are  
30 centrilobular, a bronchoscopic approach (transbronchial lung biopsy with common flexible forceps,  
31 jumbo forceps or even cryoprobes) could obviate the need of a surgical approach. In conclusion the  
32 study by Cordier JF et al [1] reminds us that a good clinical reasoning is at the basis of a well  
33 oriented research in medicine.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 References:

- 47  
48 1. Cordier JF, Cottin V, Khouatra C, Revel D, Proust C, Freymond N, Thivolet-Béjui F, Glérant  
49 JC. Hypereosinophilic obliterative bronchiolitis: a distinct unrecognized syndrome. *Eur*  
50 *Respir J* 2013 Jan 11 [Epub ahead of print]
- 51  
52 2. Hansell DM, Lynch DA, McAdams HP, Bankier AA. *Imaging of Diseases of the Chest*. Fifth  
53 edition. Mosby Elsevier 2010:752-754.  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 3. Guinee DG jr. Asthma and related eosinophilic infiltrates. In Tomasheski JF jr, Cagle PT,  
4 Farver CF, Fraire AE (Eds). *Dail and Hammar's Pulmonary Pathology*. Third Ed. Vol I  
5 Nonneoplastic lung disease. Springer 2008: 561-599.  
6  
7
- 8 4. Bain B. Eosinophilia and chronic eosinophilic leukemia, including myeloid/lymphoid  
9 neoplasms with eosinophilia and abnormalities of PDGFRA, PDGGRB, and FGFR1.  
10 In Jaffe ES, Lee Harris N, Vardiman JW, Campo E, Arber DA (Eds). *Hematopathology*  
11 Saunders Elsevier 2011: 777-787.  
12  
13
- 14 5. Poletti V, Casoni G, Zompatori M, Carloni A, Cancellieri A, Chilosi M. Bronchiolitis. In  
15 Cordier JF (Ed). *Orphan Lung Diseases. Eur Respir Mon* 2011, 54: 84-103  
16  
17
- 18 6. Travis WD. Vasculitis. In Tomasheski JF jr, Cagle PT, Farver CF, Fraire AE (Eds). *Dail and*  
19 *Hammar's Pulmonary Pathology*. Third Ed. Vol I Nonneoplastic lung disease. Springer  
20 2008:1105.  
21  
22
- 23 7. Fukushima Y, Kamiya K, Tatewaki M, Fukushima F, Hirata H, Ishii Y, Fukuda T. A patient  
24 with bronchial asthma in whom eosinophilic bronchitis and bronchiolitis developed during  
25 treatment. *Allergol Int* 2010, 59: 87-91.  
26  
27
- 28 8. Wenzel SE, Vitari CA, Shende M, Strollo M, Larkin A, Yousem SA. Asthmatic  
29 granulomatosis: a novel disease with asthmatic and granulomatous changes. *Am J Respir*  
30 *Crit Care Med* 2012, 186: 501-507.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60